Hollis talks through the investigational obesity drug and asks what the research could mean beyond the number on the scale.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Nurturher Aesthetics explains why most providers aren't using retatrutide, pointing out that the Lilly drug has no FDA approval yet.
Nurturher Aesthetics points out retatrutide has not been FDA approved and explains why most providers are not taking it themselves.
Loading…